血清高病毒载量和乙型肝炎发作孕妇的抗病毒治疗*

doi:10.3969/j.issn.1672-5069.2019.01.005

实用肝脏病杂志 ›› 2019, Vol. 22 ›› Issue (1): 13-16.doi: 10.3969/j.issn.1672-5069.2019.01.005

血清高病毒载量和乙型肝炎发作孕妇的抗病毒治疗^*

林苏, 朱月永

350005 福州市福建医科大学附属第一医院肝病研究中心

收稿日期:2018-10-29 出版日期:2019-01-10 发布日期:2019-01-16
通讯作者: 朱月永,E-mail:dr_ezhu@163.com
作者简介:林苏,女,38岁,博士研究生,副主任医师。主要从事肝病的临床研究。E-mail:sumer5129@163.com
基金资助:
*国家科技重大专项（编号:2017ZX10202201）; 福建省自然科学基金资助项目（编号：2016Y0040）; 医学科学研究基金晴众专项资助（编号： B17344）

Antiviral therapy in pregnant women with high serum viremia or hepatitis B flare

Lin Su, Zhu Yueyong.

Liver Research Center,First Affiliated Hospital,Fujian Medical University,Fuzhou 300005,Fujian Province,China

Received:2018-10-29 Online:2019-01-10 Published:2019-01-16

摘要/Abstract

关键词: 乙型肝炎, 妊娠, 高病毒载量, 治疗

Key words: Hepatitis B, Pregnancy, High viremia, Therapy

林苏, 朱月永. 血清高病毒载量和乙型肝炎发作孕妇的抗病毒治疗^*[J]. 实用肝脏病杂志, 2019, 22(1): 13-16.

Lin Su, Zhu Yueyong.. Antiviral therapy in pregnant women with high serum viremia or hepatitis B flare[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 13-16.

[1] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南(2015年版).实用肝脏病杂志,2016,19(3):Ⅴ-ⅩⅩⅢ.
[2] Giles ML,Visvanathan K,Lewin SR,et al.Chronic hepatitis B infection and pregnancy. Obstet Gynecol Surv,2012,67(1):37-44.
[3] Chang CY,Aziz N,Poongkunran M,et al.Serum alanine aminotransferase and hepatitis B DNA flares in pregnant and postpartum women with chronic hepatitis B. Am J Gastroenterol,2016,111(10):1410-1415.
[4] Dionne-Odom J,Tita AT,Silverman NS.Hepatitis B in pregnancy screening,treatment,and prevention of vertical transmission. Am J Obstetr Gynecol,2016,214(1):6-14.
[5] Visvanathan K,Dusheiko G,Giles M,et al.Managing HBV in pregnancy. Prevention,prophylaxis,treatment and follow-up:position paper produced by Australian,UK and New Zealand key opinion leaders. Gut,2015,65(2):340-350.
[6] 丁洋,尤红,任红,等. 感染乙型肝炎病毒的育龄女性临床管理共识. 临床肝胆病杂志,2018,34(6):1176-1180.
[7] Lu Y,Zhu F,Liu J,et al.The maternal viral threshold for antiviral prophylaxis of perinatal hepatitis B virus transmission in settings with limited resources:A large prospective cohort study in China. Vaccine,2017,35(48 Pt B):6627-6633.
[8] Wen W,Chang M,Zhao L,et al.Mother-to-infant transmission of hepatitis B virus infection: Significance of maternal viral load and strategies for intervention. J Hepatol,2013,59(1):24-30.
[9] Brown RS Jr,McMahon BJ,Lok AS,et al. Antiviral therapy in chronic hepatitis B viral infection during pregnancy:A systematic review and meta-analysis. Hepatology,2016,63(1):319-333.
[10] 赵媛,曹耀章,房荣,等. 替比夫定对HBV高载量孕妇母婴传播阻断的疗效及安全性:一项随机对照研究. 实用肝脏病杂志,2017,20(2):157-160.
[11] Pan CQ,Duan Z,Dai E,et al.Tenofovir to prevent hepatitis B transmission in mothers with high viral load. N Engl J Med,2016,374(24):2324-2334.
[12] Han G,Cao M,Zhao W,et al.A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. J Hepatol,2011,55(6):1215-1221.
[13] Zhang H,Pan CQ,Pang Q, et al.Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real-life practice. Hepatology,2014,60(2):468-476.
[14] Pan CQ,Han GR,Jiang HX,et al.Telbivudine prevents vertical transmission from HBeAg-positive women with chronic hepatitis B. Clin Gastroenterol Hepatol,2012,10(5):520-526.
[15] Jourdain G,Ngo-Giang-Huong N,Harrison L,et al. Tenofovir versus placebo to prevent perinatal transmission of hepatitis B. N Engl J Med,2018,378(10):911-923.
[16] Cheung KW,Seto MTY,Ng EHY.Tenofovir to prevent perinatal transmission of hepatitis B. N Engl J Med,2018,378(24):2349-2350.
[17] Gerlich W,Glebe D.Tenofovir topPrevent perinatal transmission of hepatitis B. N Engl J Med,2018,378(24):2349.
[18] Terrault NA,Feld JJ,Lok ASF.Tenofovir to prevent perinatal transmission of hepatitis B. N Engl J Med,2018,378(24):2348-2349.
[19] Chen Z,Gu G,Bian Z,et al.Clinical course and perinatal transmission of chronic hepatitis B during pregnancy:A real-world prospective cohort study. J Infect,2017,75(2):146-154.
[20] Mugwanya K,Hendrix C,Mugo N,et al.Pre-exposure prophylaxis use by breastfeeding HIV-uninfected women:A prospective short-term study of antiretroviral excretion in breast milk and infant absorption. PLoS Med,2016,13(9):e1002132.
[21] Ehrhardt S,Xie C,Guo N,et al.Breastfeeding while taking lamivudine or tenofovir disoproxil fumarate:a review of the evidence. Clin Infect Dis,2015,60(2):275-278.
[22] Sarin SK,Kumar M,Lau GK,et al.Asian-Pacific clinical practice guidelines on the management of hepatitis B:a 2015 update. Hepatol Int,2016,10(1):1-98.
[23] Han GR,Jiang HX,Wang CM,et al.Long-term safety and efficacy of telbivudine in infants born to mothers treated during the second or third trimesters of pregnancy. J Viral Hepat,2017,24(6):514-521.
[24] Shang J,Wen Q,Wang CC,et al.Safety and efficacy of telbivudine for chronic hepatitis B during the entire pregnancy:Long-term follow-up. J Viral Hepat,2017,24(Suppl 1):43-48.
[25] Siberry GK,Jacobson DL,Kalkwarf HJ,et al.Lower newborn bone mineral content associated with maternal use of tenofovir disoproxil fumarate during pregnancy. Clin Infect Dis,2015,61(6):996-1003.
[26] Gibb DM,Kizito H,Russell EC,et al.Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial. Plos Med,2012,9(5):e1001217.
[27] Terrault NA,Bzowej NH,Chang KM,et al.AASLD guidelines for treatment of chronic hepatitis B. Hepatology,2016,63(1):261-283.
[28] Ofliver EAF.EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol,2017,67(2):370-398.
[29] Sokal EM,Paganelli M,Wirth S,et al.Management of chronic hepatitis B in childhood:ESPGHAN clinical practice guidelines:consensus of an expert panel on behalf of the European Society of Pediatric Gastroenterology,Hepatology and Nutrition. J Hepatol,2013,59(4):814-829.

血清高病毒载量和乙型肝炎发作孕妇的抗病毒治疗^*

Antiviral therapy in pregnant women with high serum viremia or hepatitis B flare

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	鲍应军, 任伟新. 门静脉血栓介入治疗研究进展[J]. 实用肝脏病杂志, 2019, 22(6): 768-769.
[2]	中国研究型医院学会肝病专业委员会, 中国医师协会脂肪性肝病专家委员会. 脂肪性肝病诊疗规范化的专家建议（2019年修订版）[J]. 实用肝脏病杂志, 2019, 22(6): 787-792.
[3]	. 肝纤维化诊断及治疗共识（2019年）[J]. 实用肝脏病杂志, 2019, 22(6): 793-803.
[4]	朱凌云, 张茂海, 崔莎莎, 张秋萍. 慢性乙型肝炎患者血清IL-12、IL-18水平和外周血单个核细胞FOXp3基因水平研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 816-819.
[5]	石莹莹, 王元喜. 替比夫定联合阿德福韦酯治疗慢性乙型肝炎患者效果及其对肾功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 820-823.
[6]	闵峰, 黄文琪, 吴卫兵, 张丽, 范荣华. 慢性乙型肝炎患者血清脂肪细胞因子水平变化及其临床意义^*[J]. 实用肝脏病杂志, 2019, 22(6): 824-827.
[7]	张迎明, 申爽, 田飞, 孙园园. IFNL4和IL-28B基因多态性检测评估慢性乙型肝炎患者抗病毒治疗应答价值分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 828-831.
[8]	吴海义, 陈建新. 四种诊断模型诊断乙型肝炎病毒携带者肝纤维化的效能分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 832-835.
[9]	马丽英, 沈利娟. 妊娠后期应用替诺福韦治疗血清HBV高载量孕妇阻断HBV母婴传播的疗效及安全性分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 836-839.
[10]	邢欣, 魏重操, 周咪咪, 李小玲, 邓江, 鲁晓岚. 牛磺熊去氧胆酸与熊去氧胆酸治疗非酒精性脂肪性肝病患者疗效和安全性的Meta分析[J]. 实用肝脏病杂志, 2019, 22(6): 852-855.
[11]	汤人夷, 胡群凤, 彭莉晴. 妊娠期肝内胆汁淤积症患者血脂、肝功能和雌激素水平的变化及临床意义^*[J]. 实用肝脏病杂志, 2019, 22(6): 860-863.
[12]	段楚瑶, 陈庆山, 汪黎明, 贺晓琪. 熊去氧胆酸治疗妊娠期肝内胆汁淤积症患者疗效研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 864-867.
[13]	陈梅梅, 段晓燕, 曹海霞, 丁雯瑾. 复方鳖甲软肝片治疗原发性胆汁性肝硬化患者疗效分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 880-883.
[14]	马雅琼, 李芝兰, 夏冰. 早期肠内营养联合微生态制剂治疗肝性脑病患者肠道菌群的改变^*[J]. 实用肝脏病杂志, 2019, 22(6): 892-895.
[15]	冯文广, 姜伟, 宋国军. PPV指导术中液体治疗对行肝部分切除术治疗的肝内胆管结石患者术后并发症发生的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 912-915.